Pre-made Otilimab biosimilar ( Whole mAb, anti-CSF2 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-415
Anti-CSF2 therapeutic antibody (Pre-made Otilimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Otilimab (development codes MOR103 and GSK3196165) is a fully human antibody which has been developed by the biotechnology company MorphoSys. It can also be referred to as HuCAL antibody, HuCAL standing for Human Combinatorial Antibody Library and being a technology used to generate monoclonal antibodies. Otilimab is directed against the granulocyte-macrophage colony stimulating factor (GM-CSF), a monomeric glycoprotein functioning as a cytokine promoting both proliferation and activation of macrophages and neutrophils.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CSF2 therapeutic antibody (Pre-made Otilimab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||None|
|99% SI Structure||5c7x:MN:HL/5d7s:HL|
|95-98% SI Structure||5d72:MN:HL/5d71:HL|
|Conditions Active||Rheumatoid arthritis|
|Conditions Discontinued||Inflammation;Multiple sclerosis;Osteoarthritis|
|Development Tech||MorphoSys HuCAL Phage Display|